Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044321 | 0.83 | DRD2 (0.41) | HTR1ADRD2POLLDRD3 | |
| SCHEMBL7542801 | 0.83 | HTR2A (0.47) | HTR1ADRD2POLLDRD3CHRM2 | |
| SCHEMBL22837453 | 0.83 | HTR2A (0.47) | HTR1ADRD2POLLDRD3CHRM2 | |
| SCHEMBL22837450 | 0.81 | CETP (0.46) | HTR1ADRD2DRD3 | |
| SCHEMBL9638220 | 0.80 | ACHE (0.50) | DRD2POLL | |
| SCHEMBL15577211 | 0.80 | DRD2 (0.55) | HTR1ADRD2DRD3CHRM2CHRM1 | |
| SCHEMBL30563633 | 0.79 | ACHE (0.58) | HTR1ADRD2DRD3CHRM2CHRM1 | |
| SCHEMBL26962405 | 0.79 | ACHE (0.58) | HTR1ADRD2DRD3CHRM2CHRM1 | |
| SCHEMBL265887 | 0.79 | ACHE (0.58) | HTR1ADRD2DRD3CHRM2CHRM1 | |
| SCHEMBL598626 | 0.79 | ACHE (0.58) | HTR1ADRD2DRD3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-10316020-B2 | Indane derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-06-11 | — | — | US | disclosed |
| US-10316020-B2 | Indane derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-06-11 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3164395-B1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-20190002438-A1 | INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-01-03 | — | — | US | disclosed |
| EP-3390386-A1 | INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| CN-108473470-A | Indan derivative and application thereof as soluble guanylate cyclase activators | 诺华股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| WO-2017103888-A1 | INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| EP-3164395-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Novartis AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| CN-106470985-A | Indane and indoline derivatives as soluble guanylate cyclase activators and uses thereof | 诺华股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| WO-2016001875-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2016-01-07 | — | — | WO | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | HTR1A 313/4885DRD2 1315/4885POLL 4312/4885 |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | HAVCR2, SLC10A1, SORD | HTR1A 3673/4885DRD2 3934/4885POLL 2331/4885 |
| US-10316020-B2 | Indane derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, GUCY1B1 | HTR1A 1556/4885DRD2 2585/4885POLL 4747/4885 |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | HTR1A 313/4885DRD2 1315/4885POLL 4312/4885 |
| US-20190002438-A1 | INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, GUCY1B1 | HTR1A 1556/4885DRD2 2585/4885POLL 4747/4885 |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | HTR1A 313/4885DRD2 1315/4885POLL 4312/4885 |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | HTR1A 313/4885DRD2 1315/4885POLL 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.